Joachim Seipelt studied Biochemistry at the University of Vienna and gained pharma industry experience in doing research at Boehringer Ingelheim Vienna. After his Ph.D., he successfully established his own research group at the Max F. Perutz Laboratories in the field of virology. In 2002, Seipelt was co-­founder of AVIR Green Hills Biotechnology AG, a biotech company developing novel vaccines against influenza. As Vice president, he was responsible for the organization, business development, as well as licensing and funding. Since December 2013, he is head of the business unit “Entrepreneurship, IPR and Seedfinancing” at the Austrian federal promotional bank Austria Wirtschaftsservice GmbH. A main focus of this business unit is startup-funding for a variety of projects including high-tech, biotech, creative industry, innovative services and social business.